Biomanufacturing Media
-
End-To-End Cold Chain Management: A Next-Generation Approach
2/26/2024
Three experts in cold chain management walk through the advantages of end-to-end platforms for bulk drug substance management.
-
Cryopreservation Best Practices For Cell & Gene Therapy Source Material
2/26/2024
Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.
-
Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines
2/13/2024
In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics take audience questions regarding the stability and portability of therapeutic cancer vaccines.
-
Biotech Down Under with BiomeBank's Dr. Sam Costello
12/20/2023
Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world. In a segment of biotech that’s been particularly battered of late, that’s a big, big win.
-
Biotech Down Under With BiomeBank's Dr. Sam Costello
12/20/2023
On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind.
-
Optimizing mRNA Formulations In A Bottlenecked & Bifurcated Supply Chain
12/5/2023
Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address how to overcome the challenge of screening, developing, and optimizing formulations during preclinical development in a fragmented supply chain and outsourced environment.
-
mRNA Therapeutics: To The Liver, And Beyond!
12/5/2023
This segment from the Bioprocess Online Live event, mRNA Update: Beyond Prophylactic Vaccines, introduces guests, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D., and features Dr. VanCott addressing progress on targets beyond the liver.
-
Evaluation Criteria Of Freezer Systems For Bulk Pharmaceuticals
11/1/2023
Review data and evidence that demonstrates the benefits of an integrated approach to achieving critical end-user goals such as scalability, efficiency, sustainability, and optimized process economics.
-
CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt
10/29/2023
What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its CDMO? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?
-
CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt
10/25/2023
What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract development and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?